Literature DB >> 4835843

Development of heart valve lesions during methysergide therapy.

K A Misch.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4835843      PMCID: PMC1610207          DOI: 10.1136/bmj.2.5915.365

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  3 in total

1.  METHYSERGIDE FOR PREVENTION OF HEADACHE; EXPERIENCE IN FIVE HUNDRED PATIENTS OVER THREE YEARS.

Authors:  J R GRAHAM
Journal:  N Engl J Med       Date:  1964-01-09       Impact factor: 91.245

2.  Fibrotic syndromes with chronic use of methysergide.

Authors:  R S Kunkel
Journal:  Headache       Date:  1971-04       Impact factor: 5.887

3.  Cardiac and pulmonary fibrosis during methysergide therapy for headache.

Authors:  J R Graham
Journal:  Am J Med Sci       Date:  1967-07       Impact factor: 2.378

  3 in total
  4 in total

1.  Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin-A1.

Authors:  Leslie A Frieden; Todd A Townsend; David B Vaught; Daniel M Delaughter; Yoonha Hwang; Joey V Barnett; Jin Chen
Journal:  Dev Dyn       Date:  2010-10-19       Impact factor: 3.780

Review 2.  Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography.

Authors:  Sakima A Smith; Alan D Waggoner; Lisa de las Fuentes; Victor G Davila-Roman
Journal:  J Am Soc Echocardiogr       Date:  2009-06-23       Impact factor: 5.251

3.  Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.

Authors:  P M Coloma; M de Ridder; I Bezemer; R M C Herings; R Gini; S Pecchioli; L Scotti; P Rijnbeek; M Mosseveld; J van der Lei; G Trifirò; M Sturkenboom
Journal:  Osteoporos Int       Date:  2015-12-22       Impact factor: 4.507

4.  Drug-Induced- or Rheumatic- Valvular Heart Disease in Patients Exposed to Benfluorex?

Authors:  Florent Le Ven; Zarrin Alavi; Yannick Jobic; Yves Etienne; Romain Didier; Raphaël Porcher
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.